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Abstract
Introduction Gelsolin is an intracellular actin-binding protein
involved in cell shape changes, cell motility, and apoptosis. An
extracellular gelsolin isoform, plasma gelsolin circulates in the
blood of healthy individuals at a concentration of 200 ± 50 mg/
L and has been suggested to be a key component of an
extracellular actin-scavenging system during tissue damage.
Levels of plasma gelsolin decrease during acute injury and
inflammation, and administration of recombinant plasma gelsolin
to animals improves outcomes following sepsis or burn injuries.
In the present study, we investigated plasma gelsolin in patients
with rheumatoid arthritis.
Methods Circulating and intra-articular levels of plasma gelsolin
were measured in 78 patients with rheumatoid arthritis using a
functional (pyrene-actin nucleation) assay and compared with
62 age- and gender-matched healthy controls.
Results Circulating plasma gelsolin levels were significantly
lower in patients with rheumatoid arthritis compared with healthy
controls (141 ± 32 versus 196 ± 40 mg/L, P = 0.0002). The
patients' intra-articular plasma gelsolin levels were significantly
lower than in the paired plasma samples (94 ± 24 versus 141 ±
32 mg/L, P = 0.0001). Actin was detected in the synovial fluids
of all but four of the patients, and immunoprecipitation
experiments identified gelsolin-actin complexes.
Conclusions The plasma isoform of gelsolin is decreased in the
plasma of patients with rheumatoid arthritis compared with
healthy controls. The reduced plasma concentrations in
combination with the presence of actin and gelsolin-actin
complexes in synovial fluids suggest a local consumption of this
potentially anti-inflammatory protein in the inflamed joint.
Introduction
Plasma gelsolin (pGSN) is the extracellular isoform of a ubiq-
uitous cytoplasmic actin-binding protein, gelsolin (GSN), that
mediates cell shape changes and motility [1]. Differentially
processed mRNA transcripts present in various cell types
[2,3] and originating from a gene on chromosome 9 program
the synthesis of intracellular gelsolin (cGSN) and of its
secreted counterpart. The two isoforms are structurally and
functionally identical except for 25 additional amino acids at
the N terminus of pGSN [4]. pGSN circulates in the plasma of
healthy humans and other mammals at average levels of 200
± 50 mg/L. In every acute tissue injury setting examined,
including toxic, hyperoxic, and idiopathic lung injury, adult res-
piratory distress syndrome, acute liver injury, myonecrosis,
pancreatitis, trauma, burns, and bacterial and protozoal sepsis,
pGSN levels are subnormal [5-14].
The unifying explanation for low pGSN concentrations in acute
inflammatory conditions is the exposure by injury to plasma of
the GSN-binding ligand, actin, a major cellular constituent
ordinarily separated from the extracellular environment by
intact plasma membranes. In some but not all such cases of
cGSN: cytoplasmic gelsolin; cMMP-3: catalytic domain of matrix metalloproteinase-3; CRP: C-reactive protein; DMARD: disease-modifying anti-rheu-
matic drug; F-actin: filamentous actin; GSN: gelsolin; HRP: horseradish peroxidase; IL-6: interleukin-6; MMP: matrix metalloproteinase; MTX: meth-
otrexate; pGSN: plasma gelsolin; PVDF: polyvinylidene difluoride; RA: rheumatoid arthritis; rhpGSN: recombinant human plasma gelsolin; SB: sample 
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pGSN depletion, GSN-actin complexes are detectable in the
circulation. pGSN together with Gc-globulin, another extracel-
lular actin-binding protein, is proposed to function as an 'extra-
cellular actin scavenger system' responsible for the removal of
actin released during tissue injury [15]. Actin exposed to the
extracellular environment polymerizes into filaments (F-actin)
that stimulate downstream inflammatory reactions [16]. pGSN
has the capacity to sever and depolymerize F-actin into mono-
meric subunits (G-actin) that are then sequestered by Gc-
globulin [17] and cleared in the liver [18,19]. Administration of
pGSN to animals subjected to systemic inflammation can pro-
long survival and prevent complications of acute injury
[12,14,20]. The beneficial effect of pGSN in these settings is
unclear but may reside in its binding and/or inactivation of
inflammatory mediators such as lysophosphatidic acid, amy-
loid β protein, diadenosine 5',5"'-P1,P3-triphosphate, endo-
toxin, and platelet-activating factor) [21-26]. These findings
suggest that pGSN is a broad-spectrum anti-inflammatory
buffer and that local pGSN depletion by a shift of binding
toward actin during actin exposure following injury allows
mediators to promote appropriate defense and repair func-
tions. Catastrophic or prolonged pGSN depletion, however,
hypothetically accommodates dysfunctional and destructive
actions of the mediators, leading to secondary organ damage
and even death.
This set of events is theoretically also applicable to chronic
inflammatory conditions in which cellular damage and media-
tor release occur, but no studies have hitherto examined
pGSN levels in such states. Rheumatoid arthritis (RA) is a
chronic autoimmune disease of unknown etiology that most
prominently affects the synovial lining, resulting in a persistent
and progressive diarthrodial joint inflammation and destruc-
tion. We report here that pGSN levels are diminished in the
blood of RA patients and that analysis of synovial fluids (SFs)
suggests that pGSN is consumed in the inflamed joint. Our
findings suggest that the reason for the decreased pGSN lev-
els is local exposure of actin to the extracellular environment in
these joints.
Materials and methods
Patients
Plasma and SF samples were collected from RA patients
attending the rheumatology clinics at Sahlgrenska University
Hospital in Gothenburg for acute joint effusion. Altogether,
samples were obtained from 81 patients. Three of the patients
donated SF only. RA was diagnosed according to the Ameri-
can College of Rheumatology criteria [27]. Clinical and demo-
graphic data of the RA patient population are presented in
Table 1. At the time of SF and blood sampling, all of the
patients received non-steroidal anti-inflammatory drugs. Dis-
ease-modifying anti-rheumatic drugs (DMARDs) were admin-
istered to 45 patients, including methotrexate (MTX) (33
patients), sulfasalazine (5 patients), leflunomide (1 patient),
parenteral or oral gold salt compounds (4 patients),
cyclosporine A (5 patients: 2 in combination with MTX, 1 in
combination with leflunomide, 1 in combination with azathio-
prine, and 1 with sulfasalazine), and azathioprine (2 patients).
Nine patients received a combination of DMARD (8 patients
received MTX and 1 patient received azathioprine +
cyclosporine A) and inhibitors of tumor necrosis factor-alpha
(5 patients received infliximab and 4 patients etanercept). One
patient received MTX in combination with a soluble interleukin-
1 (IL-1) receptor agonist (anakinra). The remaining 33 patients
had no DMARD treatment at the time of blood and SF sam-
pling. Thirty-one patients used oral glucocorticosteroids
(mean dose of 6.85 mg/day). Patients receiving monotherapy
with glucocorticosteroids (n = 12) were considered as having
no DMARD treatment. Recent radiographs of the hands and
feet were obtained for all patients. The presence of bone ero-
sions defined as the loss of cortical definition of the proximal
interphalangeal, metacarpophalangeal, carpal, interphalan-
geal, and metatarsophalangeal joints was documented: a sin-
gle erosion was defined as erosive disease. The presence of
rheumatoid factor of any of the immunoglobulin isotypes
tested (IgM, IgA, and IgG) was considered as positive. The
study was approved by the Ethical Committee of the University
of Gothenburg. Informed consent was obtained from all
patients and volunteers enrolled in this study in accordance
with the Declaration of Helsinki. Control blood samples (n =
62) were obtained from volunteers donating blood at the
Blood Transfusion Unit of Sahlgrenska University Hospital and
matching the RA patients for age and gender.
Collection and preparation of samples
SF was obtained from knee joints by arthrocentesis, asepti-
cally aspirated, and transferred into tubes containing sodium
citrate (0.129 mol/L, pH 7.4). Blood samples were simultane-
ously obtained from the antecubital vein and collected into
sodium citrate anti-coagulant. Blood and SF samples were
centrifuged at 800 g for 15 minutes. Supernatants were col-
lected, separated into lots, and stored frozen at -70°C until
use.
Measurements of plasma gelsolin concentrations in 
plasma and synovial fluid
pGSN was quantified functionally by its ability to promote the
nucleation of actin filament assembly using a fluorometric
assay as previously described [14]. The assay is based on the
principle that calcium-activated pGSN binds pyrene-labeled
actin monomers to form a nucleus from which actin polymer-
izes in the pointed (slowest-growing) end direction. Pyrene-
labeled actin fluoresces with higher intensity as a polymer than
as a monomer. Pyrene actin was prepared by derivatizing actin
with N-pyrenyliodoacetamide (Molecular Probes, now part of
Invitrogen Corporation, Carlsbad, CA, USA) using the proce-
dure of Kouyama and Mihashi [28], exchanging CaCl2 for
MgCl2. Before use, pyrene actin was diluted in depolymeriza-
tion buffer (buffer A: 0.5 mM ATP, 0.5 mM β-mercaptoethanol,
2 mM Tris, 0.2 mM CaCl2, pH 7.4) to 20 μM, stored 1 hour atAvailable online http://arthritis-research.com/content/10/5/R117
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37°C to reach monomer equilibrium, and centrifuged at
250,000 g and 4°C for 30 minutes in an Optima™ TL Ultracen-
trifuge (Beckman Coulter, Inc., Fullerton, CA, USA) to pellet
any remnant F-actin. The supernatant was withdrawn and
stored in an ice water bath until use. Plasma or SF to be ana-
lyzed was diluted 1:5 in polymerization buffer (buffer B: 0.1 M
KCl, 0.2 mM MgCl2, 1.5 mM CaCl2, 0.5 mM ATP, 10 mM Tris,
0.5 mM β-mercaptoethanol, pH 7.4). Pyrene-actin fluores-
cence was recorded using a spectrofluorometer (FluoroMax-
2®; JobinYvon-Spex Instruments S.A., Inc, now HORIBA Jobin
Yvon Inc, Edison, NJ, USA). Excitation and emission wave-
lengths were 366 and 386 nm, respectively. Pyrene actin was
added to a final concentration of 1 μM in 280 μL of buffer B
containing 0.4 μM phallacidin and 5 μL of diluted sample in 6
× 50 mm borosilicate glass culture tubes (Kimble, Glass Inc,
Vineland, NJ, USA). Nucleation was monitored for 240 sec-
onds in the fluorometer following a fast vortex. The linear slope
of the fluorescence increase was calculated between 100 and
200 seconds. All of the samples were run in duplicates.
Polymerization rate in each sample was converted to pGSN
concentration by use of a standard curve of recombinant
human pGSN (rhpGSN).
Measurements of interleukin-6 levels in synovial fluid
The levels of IL-6 in SF were determined by a bioassay with a
cell clone B13.29, subclone B9, which is dependent on IL-6
for growth, as described previously [29]. The samples were
tested in 250-fold dilutions and compared with a standard
curve obtained using human recombinant IL-6 (Genzyme,
Kent, UK).
Measurements of albumin in plasma and synovial fluid
Albumin was measured by use of a kit (QuantiChrom™ BCG
Albumin Assay Kit; BioAssay Systems, Hayward, CA, USA)
according to the manufacturer's instructions.
Immunoblotting for gelsolin isoform in synovial fluid and 
gelsolin fragments in plasma
Platelet-poor plasmas or SFs were diluted 1:100 in 1× sample
buffer (SB) (10% glycerol, 2% SDS, 62.5 mM Tris-HCl,
0.03% Bromphenol blue, 5% β-mercaptoethanol, pH 6.8) to
detect GSN isoforms and 1:40 to document pGSN frag-
ments, vortexed briefly, and incubated at 97°C for 5 minutes.
Samples (10 μL for GSN isoform and 20 μL for GSN frag-
ments) were run on 10% SDS-PAGE gels in a modified Lae-
mmli system [30] and transferred to Immobilon P membranes
(polyvinylidene difluoride [PVDF]) (0.45 μm) (Millipore Corpo-
ration, Billerica, MA, USA). Platelet lysate (2 × 108/mL, 5 μL)
and rhpGSN served as negative and positive controls for
pGSN, respectively. For determination of GSN isoform, a pol-
yclonal antibody recognizing an epitope in the plasma exten-
sion of human pGSN was used (1:2,000, 2 hours, 22°C). The
antibody was designed using a peptide from the plasma exten-
sion sequence and produced by Invitrogen Corporation in rab-
bit using a KLH (keyhole limpet hemocyanin) carrier. The
antibody titer was checked at 4, 8, and 10 weeks, and the anti-
body was affinity-purified. For total GSN, the mouse mono-
Table 1
Clinical characteristics of patients with rheumatoid arthritis
Clinical characteristic Erosive RA (n = 47) Non-erosive RA (n = 31) P valuea
Gender, female/male 35/12 24/7 NS
Age, years 61.2 ± 14.1 54.2 ± 7.4 NS
Rheumatoid factor, +/- 35/12 12/19 0.008
Disease duration, years 12.1 ± 9.2 7.7 ± 7.4 0.005
Treated with DMARDs 32 13 <0.03
Methotrexate 24 (51%) 9 (29%)
Otherb 8 (17%) 4 (13%)
Non-treated 15 (32%) 18 (58%) <0.05
CRP, mg/L 42 ± 56.6 38 ± 39.6 NS
Systemic inflammation, CRP >20 mg/L 28 (60%) 18 (58%)
White blood cell count, × 109/L
Blood 8.2 ± 2.8 7.34 ± 1.1 NS
Synovial fluid 10.6 ± 17.7 13.0 ± 14.1 NS
Values are mean ± standard deviation except where otherwise indicated. aErosive versus non-erosive. bSulfasalazine 5, gold salts 4, leflunomide 1, 
cyclosporine A 5 (in combination with methotrexate 2, with azathioprine 1, with leflunomide 1, and with sulfasalazine 1), and azathioprine 2. CRP, 
C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; NS, not significant; RA, rheumatoid arthritis.Arthritis Research & Therapy    Vol 10 No 5    Osborn et al.
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clonal anti-GSN antibody 2c4 was used [31,32] (1:2,500, 2
hours, 22°C). Secondary antibodies used were goat anti-rab-
bit IgG (H+L)-horseradish peroxidase (HRP) (1:5,000, 80
minutes, 22°C) and goat anti-mouse IgG (H+L)-HRP conju-
gate, respectively (1:3,300, 80 minutes, 22°C) (Bio-Rad Lab-
oratories, Inc., Hercules, CA, USA). Chemiluminescence
detection was done using SuperSignal® West Pico Chemilu-
minescent Substrate for detection of HRP (Pierce, Rockford,
IL, USA). HyBlot CL autoradiography film (Denville Scientific
Inc., Metuchen, NJ, USA) was exposed to the membrane for 1
minute (isoform detection) or overnight (matrix metalloprotein-
ase [MMP]-cleavage product detection). The film was devel-
oped using an M35A X-OMAT Processor (Eastman Kodak
Company, Rochester, NY, USA).
The 2c4 antibody recognizes the C-terminal half of the GSN
molecule and was used for detection of approximately 42- to
46-kDa fragments by immunoblotting as previously reported
[33]. To confirm that the 2c4 antibody recognizes pGSN
cleaved by MMPs into fragments and that cleavage can occur
in plasma, rhpGSN (115 nM) or dilute human plasma (approx-
imately 115 nM pGSN) was incubated with catalytic domain
of MMP-3 (cMMP-3) (230 nM) (Sigma-Aldrich, St. Louis, MO,
USA) in 50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, and 0.5
mM ZnCl2, pH 7.5, for various time points. SDS-PAGE and
Western blots were performed as described above.
Identification of actin in synovial fluid and plasma
SFs and plasmas were pre-cleared by centrifugation at 2,500
g for 5 minutes, diluted 1:20 and 1:10 in 1 × SB, respectively,
and boiled for 10 minutes at 97°C. Samples (20 μL) were ana-
lyzed by 12% SDS-PAGE and transferred to PVDF mem-
branes as described above. Actin was identified using a
primary mouse monoclonal anti-β-actin antibody (Clone AC-
15 Mouse Ascites Fluid, 1:1,000, 2 hours, 22°C) (Sigma-
Aldrich) and a secondary (H+L)-HRP conjugated goat anti-
mouse IgG (1:3,300, 80 minutes, 22°C) (Bio-Rad Laborato-
ries, Inc.). Chemiluminescence detection was performed as
described above, exposing the film to the membrane for less
than 5 minutes. Quantification of actin in SFs and plasma was
performed by densitometry using a human actin standard
(actin protein, non-muscle) (Cytoskeleton, Inc., Denver, CO,
USA) and Scion Image 1.62a software (Scion Corporation,
Frederick, MD, USA).
Detection of gelsolin-actin complexes in synovial fluid by 
immunoprecipitation
Eleven SFs that were strongly positive for actin were centri-
fuged at 2,500 g to pellet any cellular debris. Fifty microliters
of supernatant was withdrawn and diluted 1:8 in binding buffer
(20 mM Tris, 100 mM NaCl, 1 mM CaCl2, 0.01% Tween 20,
pH 7.4). Samples were pre-cleared by incubation with 20 μL
of GammaBind Plus Sepharose (GE Healthcare, Little
Chalfont, Buckinghamshire, UK) 50/50 bead slurry for 1 hour
end-over-end at 4°C to minimize unspecific interactions with
the beads. After centrifugation to pellet beads, pre-cleared
supernatants were removed and incubated end-over-end for 1
hour at 22°C with affinity-purified mouse anti-GSN IgG (2c4,
5 μg/mL). An unspecific mouse IgG was used as a control
(normal mouse control IgG, sc-2025) (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA, USA) (5 μg/mL). Twenty microliters
50/50 bead slurry was added and incubation continued for 1
hour end-over-end. Beads were pelleted and washed four
times in binding buffer before being resuspended in 50 μL of
1 × SB, boiled for 10 minutes, and analyzed by SDS-PAGE as
described in the section above. Actin was identified using a
rabbit polyclonal IgG (anti-actin N-terminal antibody produced
in rabbit 1:750, 12 hours, 4°C) (Sigma-Aldrich) and a second-
ary (H+L)-HRP conjugated goat anti-rabbit IgG (1:2,000, 80
minutes, 22°C) (Bio-Rad Laboratories, Inc.). Chemilumines-
cence detection was performed as described above, exposing
the film to the membrane for 2 minutes.
Statistics
The levels of pGSN in the blood and SF samples were
expressed as mean ± standard deviation and as median with
interquartile range. Comparisons between the matched blood
and SF samples were analyzed by paired t test. Comparison of
pGSN and albumin levels was also performed between the
patient blood samples and the healthy controls. For further
comparison, patient material was stratified according to radio-
logical findings (erosive RA versus non-erosive RA). For the
evaluation of a possible influence of therapeutic interventions
on pGSN levels, patients were stratified according to DMARD
treatment (treated versus untreated). Differences in pGSN lev-
els in the blood and SF between the groups were calculated
separately employing the Mann-Whitney U  test. Spearman
correlation was used to determine the association between
pGSN and albumin levels in blood and SF (GraphPad Prism
software; GraphPad Software, Inc., San Diego, CA, USA). For
all of the statistical evaluation of the results, P values of below
0.05 were considered statistically significant.
Results
Plasma gelsolin levels are significantly lower in plasma 
of patients with rheumatoid arthritis compared with 
matched healthy controls
Circulating pGSN levels were significantly diminished in
patients with RA compared with those of matched healthy
controls (141 ± 32 versus 196 ± 40 mg/L, P = 0.0002) (Fig-
ure 1a). A comparison of circulating pGSN levels between RA
patients with erosive (pGSN plasma: 139.9 ± 34.1 mg/L,
pGSN SF: 92.1 ± 23.9 mg/L) and non-erosive (pGSN
plasma: 143.2 ± 28.2 mg/L, pGSN SF: 96.5 ± 24.4 mg/L)
joint disease revealed no significant differences (Figure 1b).
pGSN levels were similar in both males and females and were
not dependent on the age of the patients or on the duration of
arthritis. We observed no correlation between pGSN level and
anti-rheumatic treatment. Circulating pGSN levels were
inversely correlated to the levels of C-reactive protein (CRP) (rAvailable online http://arthritis-research.com/content/10/5/R117
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= -0.272, P = 0.026) but not related to other markers of inflam-
mation investigated, including white blood cell counts and
serum amyloid A protein (data not shown). In accordance with
other studies [34], plasma albumin concentrations were lower
in patients with RA compared with the controls (4.2 ± 0.6 ver-
sus 5.9 ± 0.6 g/dL, P < 0.0001) and lower in patients' SF than
in plasma (2.2 ± 0.5 versus 4.2 ± 0.6 g/dL, P < 0.0001).
pGSN levels in plasma and patient SF correlated positively
with albumin levels (r = 0.46, P < 0.0001 in patient plasma, r
= 0.35, P = 0.0051 in control plasma, and r = 0.2726, P =
0.0144 in SF).
To assess the impact of systemic inflammation on circulating
pGSN levels, patients were stratified according to CRP levels,
where CRP of above 20 mg/L indicated the presence of sys-
temic inflammation. The pGSN levels had a tendency to be
lower in circulation (135.8 ± 32.2 versus 148.9 ± 29.9 mg/L,
P = not significant) and in SF (92.2 ± 24.4 versus 96.3 ± 23.7
mg/L, P = not significant) of patients having systemic inflam-
mation as compared with those without. To evaluate a relation-
ship between intra-articular levels of pGSN and local
inflammation, we measured levels of IL-6 in SFs. The mean IL-
6 level was 1.59 ± 0.11 ng/mL (range of 0.03 to 4.52 ng/mL),
indicating some degree of local inflammation in most of the
samples. However, pGSN levels showed no correlation with
IL-6 levels.
Characteristics of gelsolin present in plasma and 
synovial fluid of patients with rheumatoid arthritis
Immunoblots of GSN in SF of RA patients indicated that the
GSN present in SF consists predominantly of the plasma iso-
form (Figure 2). Plasma origin of GSN was also supported by
a correlation between GSN levels in plasma and SF in the
matched pair of samples (r = 0.39, P = 0.0006). However,
pGSN functional activity in SF from RA patients was signifi-
cantly lower than that of plasma (94 ± 24 versus 141 ± 32
mg/L, P = 0.0001) as detected by its ability to promote actin
filament assembly.
In vitro, pGSN can be cleaved by MMPs into fragments of 42
to 46 kDa (at Asn416-Val417, Ser51-Met52, and Ala435-Gln436)
[33,35]. In RA, MMPs (primarily MMP-1 and MMP-3) are ele-
vated in both synovial tissue and serum [36]. Human recom-
binant pGSN as well as pGSN in plasma is cleaved in vitro
upon addition of cMMP-3 [33]. Fragments are detected by the
2c4 antibody [33] (Figure 3a,b) and thus should be recog-
nized if present in plasma or SF from RA patients. The same
total amount of pGSN was added to wells in the gels showing
in vitro cleavage as is present in gels showing the plasma and
SF samples, and thus if cleavage products were present in the
patient samples to a large extent, they would be detected.
However, the evaluation of plasma and SF for evidence of pro-
teolytic fragments of pGSN revealed no cleavage products of
pGSN detectable by SDS-PAGE after immunoblotting (Figure
3c).
Actin and gelsolin-actin complexes are present in 
synovial fluids of rheumatoid arthritis patients
Various amounts of actin were detected in SFs of 77 of the 81
RA patients and in plasmas of 19 of the 78 patients by immu-
noblotting (Figure 4a). In addition, very low concentrations of
actin were detected in 2 of the 62 plasmas from healthy con-
trols (data not shown). Concentrations of actin in patient sam-
Figure 1
Plasma gelsolin concentrations in plasma and synovial fluids (SFs) Plasma gelsolin concentrations in plasma and synovial fluids (SFs). (a) 
Plasma from matched rheumatoid arthritis (RA) patients (n = 78) and 
controls (n = 62) as well as SFs from RA patients (n = 81) were ana-
lyzed for plasma gelsolin concentration by a pyrene-actin nucleation 
assay. Data are shown as median (line in box: 197.3 mg/L for healthy 
controls, 142.8 mg/L for patient blood, and 95.6 mg/L for patient SF) 
and interquartile range (borders of box). Open dots denote outliers. 
Samples were run in duplicates. (b) Patient data stratified according to 
erosive and non-erosive RA.Arthritis Research & Therapy    Vol 10 No 5    Osborn et al.
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ples were determined using purified human actin as a
standard and ranged between 1 and 288 mg/L in SF and
between 1 and 268 mg/L in plasma. Immunoprecipitation
using the 2c4 anti-GSN antibody revealed the presence of
GSN-actin complexes in SFs of RA patients (Figure 4b).
Discussion
This is the first study to show that pGSN levels are reduced in
plasma of patients with RA. The decrease is inversely related
to the intensity of systemic inflammation, determined by an
inverse correlation with levels of acute-phase protein (CRP). In
contrast, local inflammation measured by IL-6 levels in SF has
no direct correlation with pGSN levels. The finding that circu-
lating pGSN levels decrease during chronic joint inflammation
is consistent with observations of acute inflammatory disease
states, such as sepsis and acute respiratory distress syn-
drome, in which a drop in pGSN concentration precedes more
Figure 2
Determination of gelsolin isoform in synovial fluid (SF) by  immunoblotting Determination of gelsolin isoform in synovial fluid (SF) by immunoblot-
ting. (a) Schematic of the six-domain plasma gelsolin (pGSN) mole-
cule. The respective epitopes for antibodies used are indicated. The 
2c4 antibody recognizes the C-terminal half of the GSN molecule and 
thus both cytoplasmic gelsolin (cGSN) and pGSN. The α-pGSN anti-
body recognizes the N-terminal plasma extension specific for pGSN. 
Matrix metalloproteinase-3 (MMP-3) cleavage sites [33] are also indi-
cated. (b) Identical samples were run on two separate gels and probed 
with rabbit IgG recognizing only the plasma isoform or the 2c4 antibody 
that recognizes both cytoplasmic and plasma isoforms. Band density 
was measured by Scion Image 1.62a software, and densities obtained 
for the two antibodies were compared. Data from representative immu-
noblots are shown. The relative band intensity is higher for the α-pGSN 
antibody for all of the SF samples and the plasma sample but much 
lower for the platelet lysate, which contains mainly the cGSN isoform. 
This indicates the specificity of the α-pGSN antibody for the pGSN iso-
form and shows that the main isoform in SF is pGSN (n = 3; 24 SF 
samples were analyzed). RA, rheumatoid arthritis; rhpGSN, recom-
binant human plasma gelsolin.
Figure 3
Immunoblots of plasma gelsolin (pGSN) cleavage products generated  by matrix metalloproteinase (MMP) Immunoblots of plasma gelsolin (pGSN) cleavage products generated 
by matrix metalloproteinase (MMP).(a) The catalytic domain of MMP-3 
(cMMP-3) was incubated with recombinant human pGSN (rhpGSN) at 
a 2:1 cMMP-3/pGSN ratio for various time points at 37°C. pGSN is 
cleaved and cleavage products of approximately 42 to 46 kDa are 
detected after 30 minutes of incubation using the 2c4 antibody, which 
recognizes the C-terminal half of GSN (Figure 2a) (n = 3). (b) cMMP-3 
was incubated with human plasma from healthy controls for various 
time points at 37°C. More GSN cleavage products are visible with 
increasing incubation time, indicating cleavage and showing that cleav-
age products generated by MMP-3 should be detected in plasma if 
present at high enough quantities. (Note that hrpGSN or plasma incu-
bated without cMMP-3 for 180 minutes does not show breakdown 
products.) The amount of pGSN added in (a) and (b) corresponds 
approximately to the average amount of pGSN added in (c). (c) Immu-
noblots of plasma and synovial fluid (SF) from randomly selected rheu-
matoid arthritis (RA) patient samples. MMP cleavage products are 
approximately 42 to 46 kDa in size and are recognized by 2c4 IgG (a, 
b) [33]. No cleavage products were observed in the patient samples 
(36 different plasma and SF samples were tested in three independent 
experiments). Representative immunoblots are shown.Available online http://arthritis-research.com/content/10/5/R117
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severe injuries [5-14] and the beneficial action of pGSN dur-
ing re-administration in traumatized animals suggests that it
has a protective role in inflammation [12,14,20]. The mecha-
nism behind this demonstrated protective effect during acute
inflammation is unclear but may reside in its binding and inac-
tivation of inflammatory mediators) [21-26].
pGSN was present in SFs of RA patients at a concentration of
approximately 95 mg/L. Plasma origin is supported by immu-
noblotting and a correlation between pGSN levels in plasma
and SF in the matched pair of samples. Mechanistically, pGSN
may be consumed locally through trapping at the joint space
or other affected organs in order to maintain a steady-state
concentration at the site of inflammation. pGSN has the poten-
tial to interact with several macromolecules present at sites of
inflammatory injury. In addition to its high affinity for actin, a
prime candidate for its localization at an inflamed site contain-
ing damaged cells, pGSN binds to fibronectin [37] and fibrin
[38,39], which are present at higher-than-normal concentra-
tions in the inflamed joint space during RA [40-42]. We
detected actin in 77 of the 81 SF samples and the presence
of GSN-actin complexes suggests that one function of pGSN
in the inflamed joint space is to sever F-actin exposed on dam-
aged cells during tissue injury. Hypothetically, pGSN from
blood would get trapped in the exposed actin networks, lead-
ing to a decrease in circulating pGSN. A fraction of the actin-
bound pGSN would be expected to come loose from the net-
work during the severing process and be detected as free-
floating pGSN-actin complexes in SF. Such complexes would
be interpreted as pGSN in the nucleation assay and contribute
to the total pGSN concentration measured in the patient sam-
ple. pGSN stuck in the damaged tissue would not be
detected. Gc-globulin, another component of the extracellular
actin-scavenging system, has also been shown to be present
in SF [43], suggesting a system for extracellular actin removal
in the inflamed joint. Figure 5 describes this hypothesis of
events. Since pGSN has previously been shown to bind to var-
ious inflammatory mediators such as platelet-activating factor,
lysophosphatidic acid, and endotoxin, some of which are
present at higher-than-normal levels in the inflamed synovial
joint of RA patients [44], further studies should be conducted
to understand how this local consumption due to compart-
mental actin binding affects cell activation induced by these
Figure 4
Actin and gelsolin (GSN)-actin complexes in synovial fluid (SF) Actin and gelsolin (GSN)-actin complexes in synovial fluid (SF). (a) 
Representative immunoblot showing actin in SFs of rheumatoid arthritis 
(RA) patients. The beta isoform of actin is present to various degrees in 
SF from RA patients. (b) Representative immunoblot showing results 
from immunoprecipitation of GSN-actin complexes using the 2c4 anti-
GSN antibody. SF number 23 (S23) was incubated with 2c4 or control 
IgG. Note that, when the band densities for S23 incubated with 2c4 
versus control IgG are compared, the 2c4 antibody is seen to pull 
down more actin than the control IgG, indicating that actin is bound to 
GSN in SF.
Figure 5
Proposed model of plasma gelsolin (pGSN) function in clearing actin from synovial joints of rheumatoid arthritis patients with acute joint effusion Proposed model of plasma gelsolin (pGSN) function in clearing actin from synovial joints of rheumatoid arthritis patients with acute joint effusion. (1) 
pGSN and other proteins from blood enter the inflamed synovial joint space freely due to increased permeability. (2) Actin is exposed to the extracel-
lular environment of the joint because of tissue cell damage. pGSN gets soaked up in the exposed actin networks because of its high affinity for 
actin. (3) Actin filaments (F-actin) are severed by pGSN and GSN-F-actin complexes released to the synovial fluid (SF). (4) pGSN caps the barbed 
ends of the filaments, preventing polymerization from the fast-growing ends. Due to the presence of Gc-globulin [43], the pool of free actin mono-
mers in SF is likely to be low, favoring depolymerization from the pointed (slow-growing) ends of the actin filaments. (5) Actin monomers released 
from the filaments are bound by Gc-globulin, which (6) efficiently clears it in the liver [18]. G-actin, monomeric actin.Arthritis Research & Therapy    Vol 10 No 5    Osborn et al.
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mediators. While distribution into the SF and/or local trapping
is likely to contribute to the decrease in circulating pGSN,
pGSN may also be bound to a secondary yet unidentified
plasma factor (for example, CRP) that may cause it to remain
undetected by our functional assay.
Furthermore, MMPs, considered the major enzymes responsi-
ble for the extracellular matrix degradation, cleave pGSN in
vitro [33,35] and are elevated during inflammation. It is possi-
ble that pGSN is cleaved by MMPs in vivo during RA and that
this cleavage contributes to lower levels being detected. This
is further supported by observations of MMP-mediated cleav-
age of 68-kDa secreted peptides from mutant (D187Y/N)
pGSN [45,46]. MMP-induced pGSN cleavage would most
likely be interpreted as a decrease in pGSN concentration in
our functional assay since the nucleating activity of pGSN cut
in half is weaker than for the full-length protein [47-49].
Although we did not detect proteolytic pGSN fragments by
immunoblotting, it is possible that they are further degraded or
rapidly cleared from the circulation.
Conclusion
We have documented a decrease in levels of circulating
pGSN in RA, the first example of such depletion during
chronic inflammation. pGSN levels are even lower intra-articu-
larly in affected joints. Although the cause of the decrease is
unclear and enzymatic degradation or decreased production
cannot be definitively ruled out, the capacity of pGSN to bind
several factors present in the inflamed joint space and the lack
of detection of proteolyic fragments suggest a local consump-
tion. The proportion of pGSN levels in SF versus plasma, in
combination with the observations that actin is exposed to the
extracellular environment during RA and that GSN-actin com-
plexes are present in SF, supports this hypothesis. However,
the lack of a direct relation between the degree of local inflam-
mation as measured by IL-6 and pGSN levels suggests that
the regulation of pGSN in RA is complex. Further studies on
the involvement of pGSN in RA might help in understanding
the pathogenesis and possibly aid in diagnosis and future
treatments.
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